WVE vs. LNTH, BPMC, BBIO, LEGN, ELAN, CYTK, NUVL, GRFS, VKTX, and AXSM
Should you be buying Wave Life Sciences stock or one of its competitors? The main competitors of Wave Life Sciences include Lantheus (LNTH), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Nuvalent (NUVL), Grifols (GRFS), Viking Therapeutics (VKTX), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry.
Wave Life Sciences vs.
Lantheus (NASDAQ:LNTH) and Wave Life Sciences (NASDAQ:WVE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability and media sentiment.
99.1% of Lantheus shares are held by institutional investors. Comparatively, 89.7% of Wave Life Sciences shares are held by institutional investors. 2.1% of Lantheus shares are held by insiders. Comparatively, 29.1% of Wave Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Lantheus presently has a consensus price target of $131.86, suggesting a potential upside of 44.15%. Wave Life Sciences has a consensus price target of $22.22, suggesting a potential upside of 102.20%. Given Wave Life Sciences' higher probable upside, analysts plainly believe Wave Life Sciences is more favorable than Lantheus.
Wave Life Sciences received 23 more outperform votes than Lantheus when rated by MarketBeat users. Likewise, 67.85% of users gave Wave Life Sciences an outperform vote while only 65.89% of users gave Lantheus an outperform vote.
Lantheus has a net margin of 28.57% compared to Wave Life Sciences' net margin of -66.50%. Lantheus' return on equity of 44.29% beat Wave Life Sciences' return on equity.
Lantheus has higher revenue and earnings than Wave Life Sciences. Wave Life Sciences is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.
Lantheus has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, Wave Life Sciences has a beta of -1.07, suggesting that its share price is 207% less volatile than the S&P 500.
In the previous week, Lantheus had 12 more articles in the media than Wave Life Sciences. MarketBeat recorded 22 mentions for Lantheus and 10 mentions for Wave Life Sciences. Wave Life Sciences' average media sentiment score of 0.59 beat Lantheus' score of 0.48 indicating that Wave Life Sciences is being referred to more favorably in the news media.
Summary
Lantheus beats Wave Life Sciences on 10 of the 17 factors compared between the two stocks.
Get Wave Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for WVE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Wave Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:WVE) was last updated on 1/18/2025 by MarketBeat.com Staff
